GLYC - GlycoMimetics has a new Chief Medical Officer

• GlycoMimetics ( NASDAQ: GLYC ) appoints nearly two decades of biopharmaceutical clinical development experienced Edwin Rock, M.D., Ph.D. as Chief Medical Officer (CMO).
• Most recently Edwin Rock served as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts.
• “We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as we prepare for the readout of uproleselan’s pivotal Phase 3 data in relapsed/refractory AML,” said Harout Semerjian, Chief Executive Officer.
• Shares trading up 15% premarket.

For further details see: